Vir Biotechnology (VIR) AI Stock Analysis

• Market Cap: $1.05B
• Dividend Yield: N/A
• Average Volume (3M): 1.76M
• Price to Earnings (P/E): ―
• Beta (1Y): 0.62
• Revenue Growth: -78.55%
• EPS Growth: 7.74%
• Country: US
• Employees: 408
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -1.17
• Shares Outstanding: 139,125,030
• 10 Day Avg. Volume: 1,959,643
• 30 Day Avg. Volume: 1,762,578
• PEG Ratio: 0.12
• Price to Book (P/B): 0.87
• Price to Sales (P/S): 13.48
• P/FCF Ratio: -2.20
• Enterprise Value/Market Cap: 0.92
• Enterprise Value/Revenue: 57.25
• Enterprise Value/Gross Profit: -2.20
• Enterprise Value/Ebitda: -1.89
• 1Y Price Target: $16.71
• Price Target Upside: 114.78% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 8
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 55 Neutral
• Price Target: $8.00 ▲(2.83% Upside)

The score is held back primarily by weak financial performance (continued losses and negative cash flow) and limited earnings-based valuation support (negative P/E). These are partially offset by strong technical momentum and encouraging program progress plus liquidity/runway improvements highlighted in the earnings update and recent corporate developments.

Positive Factors

Cash runway extended

A multi-year cash runway into late 2027 materially reduces near-term financing pressure and allows Vir to advance pivotal trials and registrational activities without immediate dilution. This funding visibility supports strategic partnerships and execution of clinical milestones across programs.

Positive Phase 2 SOLSTICE data

Robust, durable viral suppression with a favorable safety profile strengthens the regimen's chance to become a standard of care for chronic hepatitis delta. Positive late-stage signal enhances regulatory and commercial prospects and makes partnerships/licensing outcomes more likely and valuable.

Low leverage balance sheet

Conservative financial leverage gives Vir flexibility to fund ongoing R&D and absorb trial timing risk without excessive interest burden. Low debt improves negotiation leverage with partners and preserves capacity for opportunistic licensing or M&A to augment the pipeline.

Negative Factors

Ongoing large net losses

Sustained multi-hundred-million quarterly losses consume cash and increase reliance on external financing or milestone payments. Continued negative profitability constrains reinvestment, pressures returns for equity holders, and raises the stakes on upcoming clinical readouts for long-term viability.

Severe revenue decline

A steep drop in revenue signals limited current commercial traction or lumpy partner/milestone recognition. Without stable revenue, Vir must rely on cash, licensing, or fundraising to sustain operations, increasing execution risk and making long-term self-sufficiency dependent on successful approvals.

Binary pipeline dependence

Vir's value proposition is pipeline-driven; regulatory approvals and commercial outcomes hinge on a few pivotal trials. Binary clinical outcomes and timing uncertainty create material execution risk: negative or delayed readouts would significantly impair growth prospects and capital strategy.

Vir Biotechnology Business Overview & Revenue Model

Company Description

Vir Biotechnology, Inc., a commercial-stage immunology company, develops therapeutic products to treat and prevent serious infectious diseases. It develops Sotrovimab (VIR-7832), a SARS-CoV-2-neutralizing mAbs to treat and prevent COVID-19 infection under the Xevudy brand; VIR-2218 and VIR-3434 for the treatment of hepatitis B virus; VIR-2482 for the prevention of influenza A virus; and VIR-1111 for the prevention of human immunodeficiency virus. The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited and Brii Biosciences Offshore Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with The Rockefeller University and MedImmune, Inc.; collaboration with WuXi Biologics and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals SA. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. for the manufacture of SARS-COV-2 antibodies; and clinical collaboration with Gilead Sciences, Inc. for chronic hepatitis B virus. Vir Biotechnology, Inc. was incorporated in 2016 and is headquartered in San Francisco, California.

How the Company Makes Money

Vir Biotechnology generates revenue primarily through the development and commercialization of its therapeutic products. Key revenue streams include sales of approved products, licensing agreements, and collaborations with pharmaceutical companies. The company has entered into significant partnerships, such as its collaboration with GlaxoSmithKline for the development of COVID-19 treatments, which can lead to milestone payments and royalties on future sales. Additionally, Vir may receive funding from government grants and contracts, especially during public health emergencies, contributing to its financial earnings.

Vir Biotechnology Financial Statement Overview

Summary

Financials remain weak overall: the income statement reflects declining revenue and continued net losses, and cash flow is negative with operating and free cash outflows. The balance sheet is a relative bright spot with low leverage (debt-to-equity 0.10), but negative ROE underscores ongoing value destruction.

Income Statement

Vir Biotechnology's income statement shows significant challenges with negative net profit margins and declining revenue growth. The TTM data reveals a gross profit margin of 95.53%, but this is overshadowed by a net loss, indicating inefficiencies in cost management. The revenue growth rate is negative, reflecting a downturn in sales performance. Overall, the company is struggling to maintain profitability.

Balance Sheet

The balance sheet indicates a relatively low debt-to-equity ratio of 0.10, suggesting conservative leverage. However, the return on equity is negative, highlighting the company's inability to generate positive returns for shareholders. The equity ratio is stable, but the overall financial health is compromised by persistent losses.

Cash Flow

The cash flow statement shows negative operating and free cash flows, with a slight decline in free cash flow growth. The operating cash flow to net income ratio is negative, indicating cash flow challenges. The free cash flow to net income ratio is slightly above 1, suggesting some alignment between cash flow and reported earnings, but overall cash flow management remains a concern.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	16.86M	74.20M	86.18M	1.62B	1.10B	67.25M
Gross Profit	-438.52M	-404.44M	-486.65M	994.83M	581.54M	67.25M
EBITDA	-511.54M	-508.91M	-641.64M	839.85M	426.56M	-291.54M
Net Income	-499.65M	-521.96M	-615.06M	515.84M	528.58M	-298.67M
Balance Sheet
Total Assets	1.02B	1.40B	1.92B	2.80B	1.95B	918.76M
Cash, Cash Equivalents and Short-Term Investments	506.51M	905.35M	1.52B	2.40B	708.14M	736.86M
Total Debt	100.17M	97.89M	124.54M	127.97M	137.49M	70.18M
Total Liabilities	223.35M	248.43M	328.82M	724.13M	522.42M	201.91M
Stockholders Equity	796.10M	1.15B	1.59B	2.08B	1.43B	716.85M
Cash Flow
Free Cash Flow	-460.43M	-453.65M	-800.36M	1.60B	-69.41M	-197.49M
Operating Cash Flow	-453.54M	-446.35M	-778.78M	1.66B	-47.59M	-190.94M
Investing Cash Flow	364.46M	499.37M	164.73M	-1.19B	-140.81M	-9.86M
Financing Cash Flow	4.01M	4.39M	7.38M	34.76M	100.33M	529.47M

Vir Biotechnology Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 7.78
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Negative

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For VIR, the sentiment is Positive. The current price of 7.78 is above the 20-day moving average (MA) of 6.57, above the 50-day MA of 6.31, and above the 200-day MA of 5.57, indicating a bullish trend. The MACD of 0.42 indicates Negative momentum. The RSI at 67.50 is Neutral, neither overbought nor oversold. The STOCH value of 93.94 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for VIR.

Vir Biotechnology Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AVXL	62 Neutral	$435.13M	-9.03	-43.11%	―	―	-5.71%
VIR	55 Neutral	$1.05B	-2.15	-49.06%	―	-78.55%	7.74%
SEPN	54 Neutral	$1.06B	-15.76	-22.38%	―	2147.20%	-269.99%
IOVA	52 Neutral	$1.09B	―	-53.89%	―	175.62%	19.63%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
IVA	47 Neutral	$1.30B	-1.55	―	―	-12.52%	-82.84%
XNCR	46 Neutral	$881.92M	-6.97	-19.61%	―	38.16%	48.43%

Vir Biotechnology Corporate Events

Vir Biotechnology advances hepatitis delta program and cash runway

On January 12, 2026, Vir Biotechnology reported updated positive Phase 2 SOLSTICE data in chronic hepatitis delta showing that combination therapy with tobevibart and elebsiran achieved undetectable HDV RNA in 88% of evaluable participants at Week 96, with a favorable safety profile and stronger viral suppression than tobevibart alone, reinforcing the potential of this regimen as a future standard of care. The company outlined progress in its registrational ECLIPSE Phase 3 program in chronic hepatitis delta, highlighted upcoming presentations of Phase 1 data for PSMA-targeted T-cell engager VIR-5500 in metastatic castration-resistant prostate cancer at a major oncology meeting, and noted continued advancement of its broader PRO-XTEN oncology portfolio, while disclosing an unaudited year-end 2025 cash and investment balance of about $781 million and an extended cash runway into the fourth quarter of 2027, supported by a regional licensing deal with Norgine and disciplined spending.

The most recent analyst rating on (VIR) stock is a Buy with a $13.00 price target. To see the full list of analyst forecasts on Vir Biotechnology stock, see the VIR Stock Forecast page.

Vir Biotechnology Secures Licensing Deal with Norgine

On December 16, 2025, Vir Biotechnology entered into a license agreement with Norgine Pharma UK Limited, granting Norgine exclusive commercial rights to a combination treatment for chronic hepatitis delta (CHD) in Europe, Australia, and New Zealand. Vir will receive an initial EUR 55 million reimbursement and up to EUR 495 million in milestones, with shared clinical development costs for ongoing trials. The combination treatment of tobevibart and elebsiran showed promising results in a Phase 2 trial, achieving significant virologic suppression and being well-tolerated, which could enhance Vir’s market positioning and impact stakeholders positively.

The most recent analyst rating on (VIR) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Vir Biotechnology stock, see the VIR Stock Forecast page.